Cargando…

Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes

BACKGROUND: The major histocompatibility complex class I (MHC-I) molecule is a protein complex that displays intracellular peptides to T cells, allowing the immune system to recognize and destroy infected or cancerous cells. MHC-I is composed of a highly polymorphic HLA-encoded alpha chain that bind...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Andrea, Ozturk, Kivilcim, Pyke, Rachel Marty, Xian, Su, Zanetti, Maurizio, Carter, Hannah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657029/
https://www.ncbi.nlm.nih.gov/pubmed/31345234
http://dx.doi.org/10.1186/s12920-019-0544-1
_version_ 1783438727705526272
author Castro, Andrea
Ozturk, Kivilcim
Pyke, Rachel Marty
Xian, Su
Zanetti, Maurizio
Carter, Hannah
author_facet Castro, Andrea
Ozturk, Kivilcim
Pyke, Rachel Marty
Xian, Su
Zanetti, Maurizio
Carter, Hannah
author_sort Castro, Andrea
collection PubMed
description BACKGROUND: The major histocompatibility complex class I (MHC-I) molecule is a protein complex that displays intracellular peptides to T cells, allowing the immune system to recognize and destroy infected or cancerous cells. MHC-I is composed of a highly polymorphic HLA-encoded alpha chain that binds the peptide and a Beta-2-microglobulin (B2M) protein that acts as a stabilizing scaffold. HLA mutations have been implicated as a mechanism of immune evasion during tumorigenesis, and B2M is considered a tumor suppressor gene. However, the implications of somatic HLA and B2M mutations have not been fully explored in the context of antigen presentation via the MHC-I molecule during tumor development. To understand the effect that B2M and HLA MHC-I molecule mutations have on mutagenesis, we analyzed the accumulation of mutations in patients from The Cancer Genome Atlas according to their MHC-I molecule mutation status. RESULTS: Somatic B2M and HLA mutations in microsatellite stable tumors were associated with higher overall mutation burden and a larger fraction of HLA-binding neoantigens when compared to B2M and HLA wild type tumors. B2M and HLA mutations were highly enriched in patients with microsatellite instability. B2M mutations tended to occur relatively early during patients’ respective tumor development, whereas HLA mutations were either early or late events. In addition, B2M and HLA mutated patients had higher levels of immune infiltration by natural killer and CD8+ T cells and higher levels of cytotoxicity. CONCLUSIONS: Our findings add to a growing body of evidence that somatic B2M and HLA mutations are a mechanism of immune evasion by demonstrating that such mutations are associated with a higher load of neoantigens that should be presented via MHC-I. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12920-019-0544-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6657029
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66570292019-07-31 Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes Castro, Andrea Ozturk, Kivilcim Pyke, Rachel Marty Xian, Su Zanetti, Maurizio Carter, Hannah BMC Med Genomics Research BACKGROUND: The major histocompatibility complex class I (MHC-I) molecule is a protein complex that displays intracellular peptides to T cells, allowing the immune system to recognize and destroy infected or cancerous cells. MHC-I is composed of a highly polymorphic HLA-encoded alpha chain that binds the peptide and a Beta-2-microglobulin (B2M) protein that acts as a stabilizing scaffold. HLA mutations have been implicated as a mechanism of immune evasion during tumorigenesis, and B2M is considered a tumor suppressor gene. However, the implications of somatic HLA and B2M mutations have not been fully explored in the context of antigen presentation via the MHC-I molecule during tumor development. To understand the effect that B2M and HLA MHC-I molecule mutations have on mutagenesis, we analyzed the accumulation of mutations in patients from The Cancer Genome Atlas according to their MHC-I molecule mutation status. RESULTS: Somatic B2M and HLA mutations in microsatellite stable tumors were associated with higher overall mutation burden and a larger fraction of HLA-binding neoantigens when compared to B2M and HLA wild type tumors. B2M and HLA mutations were highly enriched in patients with microsatellite instability. B2M mutations tended to occur relatively early during patients’ respective tumor development, whereas HLA mutations were either early or late events. In addition, B2M and HLA mutated patients had higher levels of immune infiltration by natural killer and CD8+ T cells and higher levels of cytotoxicity. CONCLUSIONS: Our findings add to a growing body of evidence that somatic B2M and HLA mutations are a mechanism of immune evasion by demonstrating that such mutations are associated with a higher load of neoantigens that should be presented via MHC-I. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12920-019-0544-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-25 /pmc/articles/PMC6657029/ /pubmed/31345234 http://dx.doi.org/10.1186/s12920-019-0544-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Castro, Andrea
Ozturk, Kivilcim
Pyke, Rachel Marty
Xian, Su
Zanetti, Maurizio
Carter, Hannah
Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
title Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
title_full Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
title_fullStr Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
title_full_unstemmed Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
title_short Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
title_sort elevated neoantigen levels in tumors with somatic mutations in the hla-a, hla-b, hla-c and b2m genes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657029/
https://www.ncbi.nlm.nih.gov/pubmed/31345234
http://dx.doi.org/10.1186/s12920-019-0544-1
work_keys_str_mv AT castroandrea elevatedneoantigenlevelsintumorswithsomaticmutationsinthehlaahlabhlacandb2mgenes
AT ozturkkivilcim elevatedneoantigenlevelsintumorswithsomaticmutationsinthehlaahlabhlacandb2mgenes
AT pykerachelmarty elevatedneoantigenlevelsintumorswithsomaticmutationsinthehlaahlabhlacandb2mgenes
AT xiansu elevatedneoantigenlevelsintumorswithsomaticmutationsinthehlaahlabhlacandb2mgenes
AT zanettimaurizio elevatedneoantigenlevelsintumorswithsomaticmutationsinthehlaahlabhlacandb2mgenes
AT carterhannah elevatedneoantigenlevelsintumorswithsomaticmutationsinthehlaahlabhlacandb2mgenes